Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Claris Biotherapeutics develops biologic therapies for corneal diseases and other disorders affecting the ocular surface.
Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR molecules.
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening.
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.
Alchemab Therapeutics is developing protective antibodies designed to keep people free of hard-to-treat diseases.
Commons Clinic is a multi-specialty clinic offering minimally-invasive surgical and conservative musculoskeletal care.
Medicenna is a clinical stage, privately held, immuno-oncology company.
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Taysha Gene Therapies develops treatments to eradicate severe and life-threatening monogenic diseases of the central nervous system.
Ollin Biosciences develops ophthalmic therapies focused on treating serious vision-threatening diseases.
NorthLinks Bio is a clinical-stage biopharmaceutical company developing HEX17.
Memento Medicines is a biotech developing bispecific antibody therapies for eye diseases.
Legend Biotech is a biopharmaceutical company that develops and commercializes novel cell therapies for oncology.
Parabilis Medicines is a Grupo Bugio is a biopharmaceutical firm that specializes in creating medicines.
SonoThera develops ultrasound-based technologies for delivering genetic therapies to targeted tissues.
CervoMed a clinical-stage firm focused on discovering therapies for brain degenerative illnesses.
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Element Biosciences develops genomic sequencing and multiomics technologies used in drug discovery, and diagnostic applications.
SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.
Equillium is a biotechnology company that develops products for autoimmune and inflammatory disorders with an unmet medical need.
Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.
Atavistik Bio is a biotechnology company that develops precision allosteric small molecules aimed at treating metabolic diseases and cancer.
RA Capital Management has invested in 467 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
RA Capital Management's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Life Science. The firm invests across 16 different industry categories.
Among tracked funding rounds, Tango Therapeutics received $600.0M in a Post-IPO Equity round. RA Capital Management's total known invested capital is $56.7B.
RA Capital Management's average investment size is $123.5M across its portfolio of 467 companies.
Recent RA Capital Management portfolio additions include Claris Biotherapeutics, Scribe Therapeutics, Dyne Therapeutics, Freenome, Spero Therapeutics. These companies were founded in 2020 or later.